Drug Profile
Trametinib - Novartis
Alternative Names: 1120212; CE-Trametinib; GSK-1120212; GSK-1120212B; JTP-74057; Mecinist; Mekinist; Mekinisuto; Tasu Mekinisuto; TMT-212; Trametinib dimethyl sulfoxide; Trametinib DMSOLatest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Japan Tobacco
- Developer BeiGene; Bristol-Myers Squibb; Dana-Farber Cancer Institute; GlaxoSmithKline; GSK; Japan Tobacco; M. D. Anderson Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); Novartis; Pfizer; University of Texas M. D. Anderson Cancer Center
- Class 2 ring heterocyclic compounds; Amides; Antidementias; Antineoplastics; Cyclopropanes; Fluorobenzenes; Iodobenzenes; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Malignant melanoma; Non-small cell lung cancer
- Registered Acral lentiginous melanoma; Glioma; Solid tumours; Thyroid cancer
- Phase II Acute myeloid leukaemia; Biliary cancer; Brain metastases; Cancer; Cervical cancer; Endometrial cancer; Multiple myeloma; Myeloid leukaemia; Pancreatic cancer; Triple negative breast cancer; Uveal melanoma
- Phase I/II Colorectal cancer
- Phase I Adenocarcinoma
- No development reported Leukaemia; Lymphoma; Malignant-mesothelioma
- Discontinued Inflammation
Most Recent Events
- 12 Sep 2023 Novartis competes a phase I trial in Colorectal cancer (Combination therapy, In adults, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (PO) (NCT03714958)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease) in Germany (PO, Tablet)
- 31 Jul 2023 Novartis completes the phase III COMBI-AD trial in Malignant melanoma (Combination therapy, Adjuvant therapy) in USA, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, France, Germany, Greece, Israel, Italy, Japan, New Zealand, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, Taiwan and United Kingdom (PO, Tablet, od) (NCT01682083) (EudraCT2012-001266-15)